Despite several studies that have shown the prognostic role of SLC7A5 or SLC3A2 in cancers [11,12,13,14,15,16,17,18], the relation of their co-expression with endocrine therapy efficacy in ER+/HER2− breast cancer has yet to be reported. The gene discussed is SLC3A2; the disease is breast carcinoma.